<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803892</url>
  </required_header>
  <id_info>
    <org_study_id>DRI-2/2014 MONORAPA</org_study_id>
    <nct_id>NCT02803892</nct_id>
  </id_info>
  <brief_title>Monotherapy With Rapamycin in Long-standing Type 1 Diabetes</brief_title>
  <acronym>MONORAPA</acronym>
  <official_title>Evaluation of the Efficacy of Rapamycin and a Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) in Improving Beta Cell Function in Type 1 Diabetes of Long Duration, a Perspective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piemonti Lorenzo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Italiana Diabete Onlus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <brief_summary>
    <textblock>
      This study is a phase 2, single-center, prospective, randomized, double-blind,
      placebo-controlled, 3-arm parallel group (1:1:1) intervention trial to determine the efficacy
      of 4 weeks rapamycin treatment and 4 weeks rapamycin treatment plus 3 months vildagliptin
      treatment versus placebo in increasing endogenous insulin production and correcting glycemic
      lability. It will involve 60 patients with long standing type 1 diabetes (T1D). Patients will
      receive for one month placebo (Group 1), rapamycin plus placebo (Group 2), or rapamycin plus
      Vildagliptin (Group 3). Rapamycin will be administered at an initial dose 0.2 mg/kg orally on
      day 0 followed by 0.1 mg/kg/die (target trough levels: 8-10 ng/ml). Vildagliptin will be
      administered at a dose of 50 mg x2/die starting from day 0. After 4 weeks of treatment
      (period A), patients will discontinue rapamycin or relevant placebo treatment, but continue
      Vildagliptin or placebo for a further 8 weeks and be monitored over this period (period B).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline C-peptide response in the MMTT</measure>
    <time_frame>week 4±1, week 12±2</time_frame>
    <description>the proportion of participants with a positive response to the MMTT defined as C-peptide at 90 min &gt;0.6 ng/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline C-peptide after the MMTT</measure>
    <time_frame>week 4±1, week 12±2</time_frame>
    <description>change in the area under the curve of C-peptide after the MMTT vs baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline insulin requirement</measure>
    <time_frame>week 4±1, week 12±2</time_frame>
    <description>change in insulin requirement vs baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline fasting C-peptide</measure>
    <time_frame>week 4±1, week 12±2</time_frame>
    <description>change in fasting C-peptide vs baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline HbA1c</measure>
    <time_frame>week 4±1, week 12±2</time_frame>
    <description>change in HbA1c vs baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) related to the immunosuppression</measure>
    <time_frame>week 4±1, week 12±2</time_frame>
    <description>the incidence and severity of Adverse Events (AEs) related to the immunosuppressive treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>week 4±1, week 12±2</time_frame>
    <description>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants will be randomized to one of three treatment arms. In this arm patients will received placebo x 2 placebo (Group 1) After 4 weeks of treatment, patients will discontinue relevant placebo treatment, but continue the second placebo for a further 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Rapamycin plus Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus placebo. After 4 weeks of treatment, patients will discontinue rapamycin, but continue the second placebo for a further 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Rapamycin plus Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus vildagliptin. After 4 weeks of treatment, patients will discontinue rapamycin , but continue Vildagliptin o for a further 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapamycin</intervention_name>
    <description>Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL</description>
    <arm_group_label>Group 2: Rapamycin plus Placebo</arm_group_label>
    <arm_group_label>Group 3: Rapamycin plus Vildagliptin</arm_group_label>
    <other_name>Rapamune®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.</description>
    <arm_group_label>Group 2: Rapamycin plus Placebo</arm_group_label>
    <arm_group_label>Group 3: Rapamycin plus Vildagliptin</arm_group_label>
    <other_name>GALVUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1</intervention_name>
    <description>Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2</intervention_name>
    <description>Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged &gt;18 years, inclusive

          -  Clinical history compatible with T1D with onset of disease at &lt; 40 years of age,
             insulin dependence for ≥ 5 years at the time of enrolment

          -  C-peptide concentrations under the threshold of preserved beta cell function: fasting
             C peptide &lt;0.23 ng/ml

          -  Detectable fasting proinsulin concentrations (&gt;0.5 pmol/l)

          -  Ability to provide written informed consent

          -  Mentally stable and able to comply with the protocol procedures for the duration of
             the study, including scheduled follow-up visits and examinations

        Exclusion Criteria:

          -  Body mass index (BMI) &gt;30 kg/m2 or patient with body weight ≤40kg;

          -  Insulin requirement &gt;1.0 IU/kg/day or &lt;10 U/day;

          -  HbA1c &gt;11% (normal value: 3.5-6.0%) at the time of enrolment

          -  estimated glomerular filtration rate &lt;60 mL/min/1.73m2 calculated using the subject's
             measured serum creatinine and the Modification of Diet in Renal Disease [MDRD] study
             estimation formula)

          -  Presence or history of macroalbuminuria (&gt;300mg/g creatinine)

          -  For female subjects: positive pregnancy test, presently breast-feeding, or
             unwillingness to use effective contraceptive measures for the duration of the study
             and 4 months after discontinuation of treatment

          -  Active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB) as
             determined by a positive skin test or clinical presentation, or under treatment for
             suspected TB

          -  Any history of malignancy except for completely resected squamous or basal cell
             carcinoma of the skin

          -  Lymphopenia (&lt;1,000/μL), neutropenia (&lt;1,500/μL), or thrombocytopenia (platelets
             &lt;100,000/μL).

          -  Severe unremitting diarrhea, vomiting or other gastrointestinal disorders potentially
             interfering with the ability to absorb oral medications

          -  Any medical condition that will interfere with safe participation in the trial;

          -  Any immunosuppressive treatment at the time of enrollment.

          -  Allergy to active ingredients or to any of excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Piemonti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emanuele Bosi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorenzo Piemonti, MD</last_name>
    <phone>0226432706</phone>
    <phone_ext>+39</phone_ext>
    <email>piemonti.lorenzo@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Bolla, MD</last_name>
    <phone>0226432822</phone>
    <phone_ext>+39</phone_ext>
    <email>andrea.bolla@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Piemonti, MD</last_name>
      <email>piemonti.lorenzo@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Bolla, MD</last_name>
      <email>andrea.bolla@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Bolla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Piemonti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuele Bosi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Raffaele</investigator_affiliation>
    <investigator_full_name>Piemonti Lorenzo</investigator_full_name>
    <investigator_title>Deputy director San Raffaele Diabetes Research Institute (SR-DRI)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

